First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma: a cost-effectiveness analysis.
Xueqiong CaoMingming ZhangNa LiBin ZhengMaobai LiuXiaobing SongHongfu CaiPublished in: Therapeutic advances in medical oncology (2023)
Compared with chemotherapy alone, NC may not be a cost-effective option for treating advanced GC, GEJC, and EAC in the United States.